ArticleDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society2026
Impact of Artificial Intelligence-Assisted Endoscopy on Screening for Upper Gastrointestinal Cancer in a Large-Scale Health Screening Facility.
Article in Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI-Assisted Detection May Help Identify Visible but Missed Gastric Cancers During Routine Upper Endoscopy.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Article
- How Does Artificial Intelligence-Assisted Endoscopy Impact Upper Gastrointestinal Screening?Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesArtificial intelligence (AI)-assisted endoscopy has been developed for the early detection of upper gastrointestinal cancer; however, its clinical effectiveness remains insufficiently evaluated. This study assessed its effectiveness in a health screening facility.
methodsThis retrospective cohort study compared AI-assisted and non-AI-assisted upper gastrointestinal endoscopy at Omiya City Clinic, Japan (April 2021-March 2024). Participants who underwent endoscopy between April 2021 and March 2023 were classified as the non-AI group, while those examined between April 2023 and March 2024 comprised the AI group. The AI-assisted system was introduced in April 2023. The primary outcome was cancer detection rate (CDR), with secondary outcomes including biopsy rate and positive predictive value (PPV). Propensity score matching (PSM) was performed for age, sex, alcohol consumption, smoking, Helicobacter pylori infection history, endoscopist experience, and prior-year endoscopy to minimize bias.
resultsIn total, 17,662 were included in the AI group and 32,318 in the non-AI group. PSM created 17,662 matched pairs. In the AI group, the CDR for gastric cancer (GC) was significantly higher compared to the non-AI group (0.10% vs. 0.03%, p < 0.05). The biopsy rate was slightly higher in the AI group, with no significant difference, whereas the PPV of biopsy for gastric cancer and esophageal cancer was significantly increased (4.84% vs. 2.16%, p < 0.05).
conclusionsIn a clinical screening setting, AI-assisted endoscopy significantly improved the CDR of GC and enhanced the PPV of biopsies. These findings highlight AI-assisted endoscopy as a valuable tool for early GC diagnosis in screening environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.